Skip to main content

NRIX Nurix Therapeutics, Inc.

Healthcare

26.80 Close 10/30
Since 2024-12-02 +24.7%
Open
26.90
High
26.92
Low
25.97
Prev close
27.12
Volume
2.3M
Amplitude
3.50%
P/E
11.6
P/B
3.0
Revenue YoY (TTM)
+738.8%
52W 11.67 28.23

Is Nurix Therapeutics, Inc. a buy? Fundamentals and valuation first

As of 2026-10-30

Valuation: Fair, Quality: Strong, Momentum: Strong, Risk / liquidity: Good.

Valuation Fair Free-cash-flow yield is Top, but Price / book is Pricey.
TTM P/E 11.6 31th percentile Fair
Price / book 3.02 72th percentile Pricey
Free-cash-flow yield (%) 12.63 86th percentile Top
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Strong All 3 indicators are Top.
ROE, TTM (%) 30.45 88th percentile Top
Operating margin, TTM (%) 41.27 89th percentile Top
FCF margin, TTM (%) 52.68 93th percentile Top
Quality Factor Investing: A US Quality Value Backtest
Growth Neutral Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) 738.76 96th percentile Top
Diluted EPS growth, TTM YoY (%) -177.78 11th percentile Lagging
Momentum Strong All 2 indicators are Top.
60-day return (%) 6.26 82th percentile Top
240-day return (%) 109.38 97th percentile Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
20-day dollar volume 59,620,115 83th percentile Top
60-day annualized volatility (%) 36.56 42th percentile Good
Factor Investing Explained: 10 Classic Factors in US Stocks

Nurix Therapeutics, Inc. (NRIX) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Nurix Therapeutics, Inc. to every stock like it

AI finds several complementary traits of Nurix Therapeutics, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. (NRIX) peers and tracking

Watchlist

This page refreshes daily after the close. Add Nurix Therapeutics, Inc. to your watchlist to track signal changes on your next visit.

Nurix Therapeutics, Inc. (NRIX) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 93.29%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
13 historical occurrences (since 2021-01-25)

Average forward return after Top-quintile 6-month momentum

20-day: Win 38.5%, Sample 13, Median -12.48%, Excess -4.82%, Beat mkt rate 30.8%

60-day: Win 23.1%, Sample 13, Median -23.27%, Excess -17.56%, Beat mkt rate 23.1%

120-day: Win 18.2%, Sample 11, Median -43.9%, Excess -26.89%, Beat mkt rate 18.2%

120 days after: historical avg -24.33%

20-day -5.42%
60-day -15.63%
120-day -24.33%
20-day
60-day
120-day
Win
38.5%
23.1%
18.2%
Sample
13
13
11
Median
-12.48%
-23.27%
-43.9%
Excess
-4.82%
-17.56%
-26.89%
Beat mkt rate
30.8%
23.1%
18.2%

Over 11 occurrences, 120-day forward avg declined 24.33%, lagged the market by 26.89 pts; win rate 18.2%.

Filed revenue acceleration

Active · now 738.76%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

10 historical occurrences (since 2021-07-13)

Average forward return after Filed revenue acceleration

20-day: Win 44.4%, Sample 9, Median -6.45%, Excess +0.59%, Beat mkt rate 44.4%

60-day: Win 55.6%, Sample 9, Median +4.39%, Excess +10.72%, Beat mkt rate 55.6%

120-day: Win 66.7%, Sample 9, Median +32.06%, Excess +30.12%, Beat mkt rate 77.8%

120 days after: historical avg +34.03%

20-day +0.15%
60-day +12.25%
120-day +34.03%
20-day
60-day
120-day
Win
44.4%
55.6%
66.7%
Sample
9
9
9
Median
-6.45%
+4.39%
+32.06%
Excess
+0.59%
+10.72%
+30.12%
Beat mkt rate
44.4%
55.6%
77.8%

Over 9 occurrences, 120-day forward avg gained 34.03%, beat the market by 30.12 pts; win rate 66.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

8 times historically; 60-day forward avg +8.83%, win rate 87.5%, beating the market by +5.3 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest

8 times historically; 60-day forward avg -6.35%, win rate 28.6%, beating the market by -13.25 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.